Emergent BioSolutions

What they make

1 input Emergent BioSolutions supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Intelligence

What's known

Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.

• Incident2021

  Emergent became the face of one of the worst manufacturing failures of the pandemic. Its Bayview plant in Baltimore was contracted to mass-produce vaccine drug substance for both Johnson & Johnson and AstraZeneca at once — and workers cross-contaminated the two products, ruining an estimated 15 million doses of the J&J vaccine and prompting the FDA to halt production at the site. A congressional investigation followed, scrutinizing how so much U.S. pandemic vaccine supply had been entrusted to a single contract facility, and how a basic quality lapse there could destroy tens of millions of doses overnight. The episode is a stark single-site chokepoint failure — echoing the Hospira, Intas and GE-Shanghai shortages elsewhere in this radar — made more pointed because the stumbling company is also the one the nation relies on for biodefense. It crystallized a hard lesson: concentrating critical drug manufacturing in one plant creates enormous fragility, and even a strategically vital supplier can fail catastrophically when scaled up too fast under pressure.

  Emergent BioSolutions Inc. (EBS) ↗

• Did you know2024

  Emergent BioSolutions makes NARCAN — the over-the-counter nasal spray that reverses opioid overdoses and now sits in countless first-aid kits, schools and paramedics' bags. But its core business is something most people never think about: biodefense. Emergent is the U.S. government's primary supplier of medical countermeasures against biological attack, making the nation's anthrax vaccine (BioThrax) and smallpox vaccine (ACAM2000) and antitoxins that are held in the Strategic National Stockpile for use after a bioterror event or pandemic. So one company stands behind both the everyday harm-reduction tool used in the opioid crisis and the secret national stockpile meant to protect Americans from anthrax or smallpox terrorism. From a drug-overdose on a city street to a bioweapon attack, two utterly different public-health emergencies are answered, in part, by the same Maryland company — an unusual span from consumer harm-reduction to national-security medicine.

  Emergent BioSolutions Inc. (EBS) ↗

• Concentration2024

  Emergent embodies the dilemma of sole-source national-security supply. For years it has been effectively the only maker of the U.S. anthrax vaccine, and a primary supplier of other countermeasures the government stockpiles for biological threats — a position that gives it dependable federal contracts but has repeatedly drawn scrutiny over cost, reliability and the risk of depending on a single company for products with no commercial market but enormous strategic importance. Because there's no real demand for an anthrax vaccine outside government preparedness, the normal market won't sustain multiple competing suppliers, so the country is left relying on one firm to be ready for a threat that may never come but would be catastrophic if it did. It's a distinctive kind of chokepoint: not a popular product made by too few makers, but an unprofitable-yet-essential one that only exists because the government pays a single company to keep the capability alive — and whose reliability, as the Bayview failure showed, is itself a national-security variable.

  Emergent BioSolutions Inc. (EBS) ↗